[HTML][HTML] All disease begins in the (leaky) gut: role of zonulin-mediated gut permeability in the pathogenesis of some chronic inflammatory diseases

A Fasano - F1000Research, 2020 - ncbi.nlm.nih.gov
Improved hygiene leading to reduced exposure to microorganisms has been implicated as
one possible cause for the recent “epidemic” of chronic inflammatory diseases (CIDs) in …

Challenges, progress, and prospects of developing therapies to treat autoimmune diseases

L Fugger, LT Jensen, J Rossjohn - Cell, 2020 - cell.com
Autoimmune diseases are a result of the immune system being misdirected toward its host
and have major and increasing unmet clinical needs. In general, present therapies are …

[HTML][HTML] Multisystem inflammatory syndrome in children is driven by zonulin-dependent loss of gut mucosal barrier

LM Yonker, T Gilboa, AF Ogata… - The Journal of …, 2021 - Am Soc Clin Investig
Multisystem inflammatory syndrome in children (MIS-C) occurs during or recently following
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and is …

Zonulin, a regulator of epithelial and endothelial barrier functions, and its involvement in chronic inflammatory diseases

C Sturgeon, A Fasano - Tissue barriers, 2016 - Taylor & Francis
Beside digesting nutrients and absorbing solutes and electrolytes, the intestinal epithelium
with its barrier function is in charge of a tightly controlled antigen trafficking from the …

[HTML][HTML] Target specific tight junction modulators

J Brunner, S Ragupathy, G Borchard - Advanced drug delivery reviews, 2021 - Elsevier
Intercellular tight junctions represent a formidable barrier against paracellular drug
absorption at epithelia (eg, nasal, intestinal) and the endothelium (eg, blood–brain barrier) …

Intestinal permeation enhancers for oral peptide delivery

S Maher, RJ Mrsny, DJ Brayden - Advanced drug delivery reviews, 2016 - Elsevier
Intestinal permeation enhancers (PEs) are one of the most widely tested strategies to
improve oral delivery of therapeutic peptides. This article assesses the intestinal permeation …

Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial

DA Leffler, CP Kelly, PHR Green, RN Fedorak… - Gastroenterology, 2015 - Elsevier
Background & Aims Celiac disease (CeD) is a prevalent autoimmune condition. Recurrent
signs and symptoms are common despite treatment with a gluten-free diet (GFD), yet no …

The intestinal barrier in multiple sclerosis: implications for pathophysiology and therapeutics

CR Camara-Lemarroy, L Metz, JB Meddings… - Brain, 2018 - academic.oup.com
Biological barriers are essential for the maintenance of homeostasis in health and disease.
Breakdown of the intestinal barrier is an essential aspect of the pathophysiology of …

[HTML][HTML] Celiac disease: role of the epithelial barrier

M Schumann, B Siegmund, JD Schulzke… - Cellular and molecular …, 2017 - Elsevier
In celiac disease (CD) a T-cell–mediated response to gluten is mounted in genetically
predisposed individuals, resulting in a malabsorptive enteropathy histologically highlighted …

Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo‐controlled study

CP Kelly, PHR Green, JA Murray… - Alimentary …, 2013 - Wiley Online Library
Background Coeliac disease, an autoimmune disorder triggered by gluten ingestion, is
managed by a gluten‐free diet (GFD), which is difficult for many patients. Larazotide acetate …